Skip to main content
Erschienen in: Neurocritical Care 3/2022

13.04.2022 | Review Article

A Comparison Between Enteral and Intravenous Nimodipine in Subarachnoid Hemorrhage: A Systematic Review and Network Meta-Analysis

verfasst von: Federico Geraldini, Alessandro De Cassai, Paolo Diana, Christelle Correale, Annalisa Boscolo, Stefano Zampirollo, Laura Disarò, Anna Carere, Nicola Cacco, Paolo Navalesi, Marina Munari

Erschienen in: Neurocritical Care | Ausgabe 3/2022

Einloggen, um Zugang zu erhalten

Abstract

Our objective was to compare the effectiveness of intravenous and enteral nimodipine in preventing poor outcome from delayed cerebral ischemia in patients with subarachnoid hemorrhage. We performed a systematic search and a network meta-analysis using the following databases: PubMed, Scopus, the Cochrane Central Register of Controlled Trials, and Google Scholar. Risk of Bias 2 tool was used to assess risk of bias of included studies. A ranking among methods was performed on the basis of the frequentist analog of the surface under the cumulative ranking curve. Published studies that met the following population, intervention, comparison, outcomes and study (PICOS) criteria were included: patients with subarachnoid hemorrhage aged 15 years or older (P); nimodipine, intravenous and oral formulation (I); placebo or no intervention (C); poor outcome measured at 3 months (defined as death, vegetative state, or severe disability), case fatality at 3 months, delayed cerebral ischemia, delayed ischaemic neurologic deficit, and vasospasm measured with transcranial Doppler or digital subtraction angiography (O); and randomized controlled trials (S). No language or publication date restrictions were applied. Ten studies were finally included, with a total of 1527 randomly assigned patients. Oral and intravenous nimodipine were both effective in preventing poor outcome, delayed cerebral ischemia, and delayed ischaemic neurological deficit. Neither treatment was effective in improving case fatality. Evolving clinical protocols over a 30-year period and the risk of bias of the included studies may limit the strength of our results. Enteral and intravenous nimodipine may have a similar effectiveness in terms of preventing poor outcome, delayed cerebral ischemia, and delayed ischaemic neurological deficit. More research may be needed to fully establish the role of intravenous nimodipine in current clinical practice.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Connolly ES Jr, Rabinstein AA, Carhuapoma JR, et al. Guidelines for the management of aneurysmal subarachnoid hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2012;43(6):1711–37.CrossRef Connolly ES Jr, Rabinstein AA, Carhuapoma JR, et al. Guidelines for the management of aneurysmal subarachnoid hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2012;43(6):1711–37.CrossRef
2.
Zurück zum Zitat Steiner T, Juvela S, Unterberg A, Jung C, Forsting M, Rinkel G. European stroke organization guidelines for the management of intracranial aneurysms and subarachnoid haemorrhage. Cerebrovasc Dis. 2013;35(2):93–112.CrossRef Steiner T, Juvela S, Unterberg A, Jung C, Forsting M, Rinkel G. European stroke organization guidelines for the management of intracranial aneurysms and subarachnoid haemorrhage. Cerebrovasc Dis. 2013;35(2):93–112.CrossRef
3.
Zurück zum Zitat Cho W-S, Kim JE, Park SQ, et al. Korean clinical practice guidelines for aneurysmal subarachnoid hemorrhage. J Korean Neurosurg Soc. 2018;61(2):127–66.CrossRef Cho W-S, Kim JE, Park SQ, et al. Korean clinical practice guidelines for aneurysmal subarachnoid hemorrhage. J Korean Neurosurg Soc. 2018;61(2):127–66.CrossRef
4.
Zurück zum Zitat Soppi V, Karamanakos PN, Koivisto T, et al. A randomized outcome study of enteral versus intravenous nimodipine in 171 patients after acute aneurysmal subarachnoid hemorrhage. World Neurosurg. 2012;78(1–2):101–9.CrossRef Soppi V, Karamanakos PN, Koivisto T, et al. A randomized outcome study of enteral versus intravenous nimodipine in 171 patients after acute aneurysmal subarachnoid hemorrhage. World Neurosurg. 2012;78(1–2):101–9.CrossRef
5.
Zurück zum Zitat Kronvall E, Undrén P, Romner B, Säveland H, Cronqvist M, Nilsson OG. Nimodipine in aneurysmal subarachnoid hemorrhage: a randomized study of intravenous or peroral administration: clinical article. J Neurosurg. 2009;110(1):58–63.CrossRef Kronvall E, Undrén P, Romner B, Säveland H, Cronqvist M, Nilsson OG. Nimodipine in aneurysmal subarachnoid hemorrhage: a randomized study of intravenous or peroral administration: clinical article. J Neurosurg. 2009;110(1):58–63.CrossRef
7.
Zurück zum Zitat Abboud T, Andresen H, Koeppen J, et al. Serum levels of nimodipine in enteral and parenteral administration in patients with aneurysmal subarachnoid hemorrhage. Acta Neurochir (Wien). 2015;157(5):763–7.CrossRef Abboud T, Andresen H, Koeppen J, et al. Serum levels of nimodipine in enteral and parenteral administration in patients with aneurysmal subarachnoid hemorrhage. Acta Neurochir (Wien). 2015;157(5):763–7.CrossRef
8.
Zurück zum Zitat Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339(jul21 1):b2700. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339(jul21 1):b2700.
9.
Zurück zum Zitat Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;l4898. Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;l4898.
10.
Zurück zum Zitat Puhan MA, Schünemann HJ, Murad MH, et al. A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis. BMJ 2014;349(sep24 5):g5630. Puhan MA, Schünemann HJ, Murad MH, et al. A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis. BMJ 2014;349(sep24 5):g5630.
11.
Zurück zum Zitat Rücker G, Schwarzer G. Ranking treatments in frequentist network meta-analysis works without resampling methods. BMC Med Res Methodol. 2015;15(1):58.CrossRef Rücker G, Schwarzer G. Ranking treatments in frequentist network meta-analysis works without resampling methods. BMC Med Res Methodol. 2015;15(1):58.CrossRef
12.
Zurück zum Zitat Higgins JPT. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–60.CrossRef Higgins JPT. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–60.CrossRef
13.
Zurück zum Zitat Pickard JD, Murray GD, Illingworth R, et al. Effect of oral nimodipine on cerebral infarction and outcome after subarachnoid haemorrhage: British aneurysm nimodipine trial. BMJ. 1989;298(6674):636–42.CrossRef Pickard JD, Murray GD, Illingworth R, et al. Effect of oral nimodipine on cerebral infarction and outcome after subarachnoid haemorrhage: British aneurysm nimodipine trial. BMJ. 1989;298(6674):636–42.CrossRef
14.
Zurück zum Zitat Petruk KC, West M, Mohr G, et al. Nimodipine treatment in poor-grade aneurysm patients: results of a multicenter double-blind placebo-controlled trial. J Neurosurg. 1988;68(4):505–17.CrossRef Petruk KC, West M, Mohr G, et al. Nimodipine treatment in poor-grade aneurysm patients: results of a multicenter double-blind placebo-controlled trial. J Neurosurg. 1988;68(4):505–17.CrossRef
15.
Zurück zum Zitat Neil-Dwyer G, Mee E, Dorrance D, Lowe D. Early intervention with nimodipine in subarachnoid haemorrhage. Eur Heart J. 1987;8 Suppl K:41–7. Neil-Dwyer G, Mee E, Dorrance D, Lowe D. Early intervention with nimodipine in subarachnoid haemorrhage. Eur Heart J. 1987;8 Suppl K:41–7.
16.
Zurück zum Zitat Ohman J, Servo A, Heiskanen O. Long-term effects of nimodipine on cerebral infarcts and outcome after aneurysmal subarachnoid hemorrhage and surgery. J Neurosurg. 1991;74(1):8–13.CrossRef Ohman J, Servo A, Heiskanen O. Long-term effects of nimodipine on cerebral infarcts and outcome after aneurysmal subarachnoid hemorrhage and surgery. J Neurosurg. 1991;74(1):8–13.CrossRef
17.
Zurück zum Zitat Philippon J, Grob R, Dagreou F, Guggiari M, Rivierez M, Viars P. Prevention of vasospasm in subarachnoid haemorrhage. A controlled study with nimodipine. Acta Neurochir (Wien). 1986;82(3–4):110–4. Philippon J, Grob R, Dagreou F, Guggiari M, Rivierez M, Viars P. Prevention of vasospasm in subarachnoid haemorrhage. A controlled study with nimodipine. Acta Neurochir (Wien). 1986;82(3–4):110–4.
18.
Zurück zum Zitat Allen GS, Ahn HS, Preziosi TJ, et al. Cerebral arterial spasm–a controlled trial of nimodipine in patients with subarachnoid hemorrhage. N Engl J Med. 1983;308(11):619–24.CrossRef Allen GS, Ahn HS, Preziosi TJ, et al. Cerebral arterial spasm–a controlled trial of nimodipine in patients with subarachnoid hemorrhage. N Engl J Med. 1983;308(11):619–24.CrossRef
19.
Zurück zum Zitat Messeter K, Brandt L, Ljunggren B, et al. Prediction and prevention of delayed ischemic dysfunction after aneurysmal subarachnoid hemorrhage and early operation. Neurosurgery. 1987;20(4):548–53.CrossRef Messeter K, Brandt L, Ljunggren B, et al. Prediction and prevention of delayed ischemic dysfunction after aneurysmal subarachnoid hemorrhage and early operation. Neurosurgery. 1987;20(4):548–53.CrossRef
20.
Zurück zum Zitat Reif W, Gaab MR, Stolke D, Höllerhage HG, Dietz H. Parenteral nimodipine therapy after subarachnoid hemorrhage: a randomized clinical study. In: Stabilizing Craniocervical Operations Calcium Antagonists in SAH Current Legal Issues. Berlin, Heidelberg: Springer Berlin Heidelberg; 1990. p. 222–6. Reif W, Gaab MR, Stolke D, Höllerhage HG, Dietz H. Parenteral nimodipine therapy after subarachnoid hemorrhage: a randomized clinical study. In: Stabilizing Craniocervical Operations Calcium Antagonists in SAH Current Legal Issues. Berlin, Heidelberg: Springer Berlin Heidelberg; 1990. p. 222–6.
21.
Zurück zum Zitat Jan M, Buchheit F, Tremoulet M. Therapeutic trial of intravenous nimodipine in patients with established cerebral vasospasm after rupture of intracranial aneurysms. Neurosurgery. 1988;23(2):154–7.CrossRef Jan M, Buchheit F, Tremoulet M. Therapeutic trial of intravenous nimodipine in patients with established cerebral vasospasm after rupture of intracranial aneurysms. Neurosurgery. 1988;23(2):154–7.CrossRef
23.
Zurück zum Zitat Han DH, Lee SH, Lee SH. Effect of nimodipine treatment on outcome in surgical cases of aneurysmal SAH. J Neurosurg. 1993;78:346. Han DH, Lee SH, Lee SH. Effect of nimodipine treatment on outcome in surgical cases of aneurysmal SAH. J Neurosurg. 1993;78:346.
24.
Zurück zum Zitat Wienke A, Wurm F, Vogel A-S, et al. Enteral or parenteral nimodipine treatment: a comparative pharmacokinetic study. J Neurol Surg A Cent Eur Neurosurg. 2013;75(02):084–90.CrossRef Wienke A, Wurm F, Vogel A-S, et al. Enteral or parenteral nimodipine treatment: a comparative pharmacokinetic study. J Neurol Surg A Cent Eur Neurosurg. 2013;75(02):084–90.CrossRef
25.
Zurück zum Zitat Porchet F, Chioléro R, de Tribolet N. Hypotensive effect of nimodipine during treatment for aneurysmal subarachnoid haemorrhage. Acta Neurochir (Wien). 1995;137(1–2):62–9.CrossRef Porchet F, Chioléro R, de Tribolet N. Hypotensive effect of nimodipine during treatment for aneurysmal subarachnoid haemorrhage. Acta Neurochir (Wien). 1995;137(1–2):62–9.CrossRef
26.
Zurück zum Zitat Dorhout Mees SM, Rinkel GJE, Feigin VL, et al. Calcium antagonists for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev. 2007;(3):CD000277. Dorhout Mees SM, Rinkel GJE, Feigin VL, et al. Calcium antagonists for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev. 2007;(3):CD000277.
27.
Zurück zum Zitat Liu GJ, Luo J, Zhang LP, et al. Meta-analysis of the effectiveness and safety of prophylactic use of nimodipine in patients with an aneurysmal subarachnoid haemorrhage. CNS Neurol Disord Drug Targets. 2011;10(7):834–44.CrossRef Liu GJ, Luo J, Zhang LP, et al. Meta-analysis of the effectiveness and safety of prophylactic use of nimodipine in patients with an aneurysmal subarachnoid haemorrhage. CNS Neurol Disord Drug Targets. 2011;10(7):834–44.CrossRef
28.
Zurück zum Zitat Yu W, Huang Y, Zhang X, et al. Effectiveness comparisons of drug therapies for postoperative aneurysmal subarachnoid hemorrhage patients: network meta-analysis and systematic review. BMC Neurol. 2021;21(1):294.CrossRef Yu W, Huang Y, Zhang X, et al. Effectiveness comparisons of drug therapies for postoperative aneurysmal subarachnoid hemorrhage patients: network meta-analysis and systematic review. BMC Neurol. 2021;21(1):294.CrossRef
30.
Metadaten
Titel
A Comparison Between Enteral and Intravenous Nimodipine in Subarachnoid Hemorrhage: A Systematic Review and Network Meta-Analysis
verfasst von
Federico Geraldini
Alessandro De Cassai
Paolo Diana
Christelle Correale
Annalisa Boscolo
Stefano Zampirollo
Laura Disarò
Anna Carere
Nicola Cacco
Paolo Navalesi
Marina Munari
Publikationsdatum
13.04.2022
Verlag
Springer US
Erschienen in
Neurocritical Care / Ausgabe 3/2022
Print ISSN: 1541-6933
Elektronische ISSN: 1556-0961
DOI
https://doi.org/10.1007/s12028-022-01493-4

Weitere Artikel der Ausgabe 3/2022

Neurocritical Care 3/2022 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Schützt Olivenöl vor dem Tod durch Demenz?

10.05.2024 Morbus Alzheimer Nachrichten

Konsumieren Menschen täglich 7 Gramm Olivenöl, ist ihr Risiko, an einer Demenz zu sterben, um mehr als ein Viertel reduziert – und dies weitgehend unabhängig von ihrer sonstigen Ernährung. Dafür sprechen Auswertungen zweier großer US-Studien.

Bluttest erkennt Parkinson schon zehn Jahre vor der Diagnose

10.05.2024 Parkinson-Krankheit Nachrichten

Ein Bluttest kann abnorm aggregiertes Alpha-Synuclein bei einigen Menschen schon zehn Jahre vor Beginn der motorischen Parkinsonsymptome nachweisen. Mit einem solchen Test lassen sich möglicherweise Prodromalstadien erfassen und die Betroffenen früher behandeln.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Wartezeit nicht kürzer, aber Arbeit flexibler

Psychotherapie Medizin aktuell

Fünf Jahren nach der Neugestaltung der Psychotherapie-Richtlinie wurden jetzt die Effekte der vorgenommenen Änderungen ausgewertet. Das Hauptziel der Novellierung war eine kürzere Wartezeit auf Therapieplätze. Dieses Ziel wurde nicht erreicht, es gab jedoch positive Auswirkungen auf andere Bereiche.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.